MiMedx Group, Inc. reports results for the quarter ended September 30 - Earnings Summary

• MiMedx Group, Inc. reported a quarterly adjusted loss of 1 cent​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 15 cents. The mean expectation of five analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -2 cents to -1 cents per share.

• Revenue fell 45.2% to $62.28 million from a year ago; analysts expected $68.55 million.

• MiMedx Group, Inc.'s reported EPS for the quarter was a loss of 6 cents​.

• The company reported a quarterly loss of $8.68 million.

• MiMedx Group, Inc. shares had fallen by 16.3% this quarter and lost 42.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 33.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for MiMedx Group, Inc. is $8.00, about 51.2% above its last closing price of $3.90

This summary was machine generated from LSEG data October 28 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)